{
    "clinical_study": {
        "@rank": "109091", 
        "acronym": "EVACEL", 
        "arm_group": {
            "arm_group_label": "embolization or chemoembolization plus everolimus", 
            "arm_group_type": "Experimental", 
            "description": "After 2 sessions of embolization with microsphere of 100 to 500 \u00b5m or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site)."
        }, 
        "brief_summary": {
            "textblock": "Determine wether 24 months treatment with everolimus prolongs progression free survival rate\n      (based on a central assessment) after embolisation ou chemoembolisation for liver\n      metastases.\n\n        -  H0 a 24 months progression free survival rate less than 35% is unacceptable\n\n        -  H1 a 24 months progression free survival rate greater than 35% would show that\n           everolimus treatment is beneficial, the expected 24 months progression free survival\n           rate being 50%"
        }, 
        "brief_title": "Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuroendocrine Tumors", 
            "Hepatic Metastases", 
            "Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Endocrine Gland Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Neuroendocrine Tumors", 
                "Liver Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Well differentiated (grade 1 and 2 according to WHO classification 2010 appendix 2),\n             histologically-proven endocrine tumor of the gastrointestinal tract (TENpath review\n             mandatory),\n\n          -  Measurable liver metastasis (or metastases) as defined in RECIST v1.1 that are\n             unresectable and inaccessible to radiofrequency ablation-type local treatment\n\n          -  Hepatic arterial embolization or chemoembolization indicated for tumor size\n             reduction, confirmed in an multidisciplinary team (MDT) meeting, due to the\n             progressive nature of the liver metastases (morphological progression during the past\n             12 months as defined in RECIST v1.1)\n\n          -  Age \u2265 18 years\n\n          -  WHO performance status \u2264 2\n\n          -  No contraindications to embolization or chemoembolization  or everolimus\n\n          -  Satisfactory laboratory assessments:Neutrophil count \u2265 1.5 x 109/L, platelet count \u2265\n             100 x 109/L, Hb > 10 g/dL, serum bilirubin \u2264 1.5 x the upper limit of normal (ULN),\n             INR < 1.3 (or < 3 for patients on anticoagulant therapy) ALT and AST \u2264 5 x ULN,\n             creatinine \u2264 1.5 x ULN, fasting serum cholesterol \u2264 300 mg/dL or 7.75 mmol/L and\n             triglycerides \u2264 2.5 x ULN (if either or both of these limits are exceeded, the\n             patient may only be included into the study after institution of appropriate\n             lipid-lowering therapy)\n\n          -  Complete resolution of toxic effects of any prior treatments, or persistence at grade\n             1 at most (CTCAE version 4.0)\n\n          -  Minimum time since previous treatment: 28 days\n\n          -  Patient has been informed and has signed an informed consent form, after verification\n             of the eligibility criteria\n\n          -  Patient covered by a French national health insurance scheme\n\n        Exclusion Criteria:\n\n          -  Duodenopancreatic neuroendocrine tumor\n\n          -  Poorly differentiated and/or grade 3 endocrine tumor,\n\n          -  Embolization or chemoembolization  indicated for symptomatic control only\n\n          -  Prior hepatic TACE or embolization\n\n          -  Prior treatment with an mTOR inhibitor (somatostatin analogs to control secretion are\n             permitted)\n\n          -  Symptomatic bone metastasis (or metastases)\n\n          -  Any uncontrolled progressive disease: hepatic failure, renal failure, respiratory\n             failure, NYHA class III-IV congestive heart failure, unstable angina, myocardial\n             infarction, significant arrhythmia\n\n          -  Interstitial lung disease\n\n          -  Uncontrolled diabetes, defined by HbA1c > 8%\n\n          -  Chronic corticosteroid or immunosuppressant therapy\n\n          -  Hypersensitivity to everolimus, other rapamycin derivatives, or one of the excipients\n\n          -  Major surgery, open biopsy, or significant traumatic lesion during the 28 days prior\n             to starting the investigational treatment Incompletely healed wound or foreseeable\n             need for major surgery during the study\n\n          -  Contraindication to vascular occlusion procedures: Portal thrombosis, biliodigestive\n             anastomosis\n\n          -  Malignancy during the past 5 years, with the exception of curatively treated basal\n             cell skin carcinoma or in situ cervical cancer\n\n          -  Foreseeable non-compliance\n\n          -  Medical, geographic, sociological, psychological, or legal situation that would\n             preclude the patient from completing the study or signing an informed consent form\n\n          -  Pregnant or breast-feeding women\n\n          -  Men or women of child-bearing potential not using effective contraception\n\n          -  Concurrent participation in another investigational study that could affect the\n             primary endpoint of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678664", 
            "org_study_id": "FFCD 1104"
        }, 
        "intervention": [
            {
                "arm_group_label": "embolization or chemoembolization plus everolimus", 
                "description": "10 mg per day of everolimus during 24 months or until progression disease", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "embolization or chemoembolization plus everolimus", 
                "description": "2 sessions embolization with spheric particles", 
                "intervention_name": "embolization", 
                "intervention_type": "Device", 
                "other_name": "spheric particules of 100 to 500 \u00b5m"
            }, 
            {
                "arm_group_label": "embolization or chemoembolization plus everolimus", 
                "description": "2 sessions chemoembolization with 10 mg of lipiodol with  100 mg of doxorubicine", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Chemoembolization"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cancer", 
            "neuroendocrine tumors", 
            "gastrointestinal tract", 
            "metastases", 
            "liver", 
            "hepatic"
        ], 
        "lastchanged_date": "January 2, 2013", 
        "location": {
            "contact": {
                "email": "marie.moreau@u-bourgogne.fr", 
                "last_name": "Marie MOREAU", 
                "phone": "+33 (0)3 80 39 34 04"
            }, 
            "contact_backup": {
                "email": "martina.schneider@u-bourgogne.fr", 
                "last_name": "Martina SCHNEIDER", 
                "phone": "+33 (0)3 80 66 80 13"
            }, 
            "facility": {
                "address": {
                    "city": "Dijon", 
                    "country": "France", 
                    "state": "C\u00f4te d'Or", 
                    "zip": "21000"
                }, 
                "name": "F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive"
            }, 
            "investigator": {
                "last_name": "Come LEPAGE, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors", 
        "overall_contact": {
            "email": "emmanuel.mitry@curie.net", 
            "last_name": "Emmanuel MITRY, PhD", 
            "phone": "+33 (0)1 47 11 15 29"
        }, 
        "overall_contact_backup": {
            "email": "marie.moreau@u-bourgogne.fr", 
            "last_name": "Marie MOREAU", 
            "phone": "+33 (0)3 80 39 34 04"
        }, 
        "overall_official": {
            "affiliation": "Institut Curie", 
            "last_name": "Emmanuel MITRY, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hepatic progression free survival rate as defined in RECIST 1.1 (with death considered as progression) during the 24 months of treatment with everolimus (appendix 3).\nProgression-free survival rate (PFS) (based on the central assessment) according to RECIST v1.1 according to RECIST v1.1 will be defined as the time from the date of inclusion to the date of hepatic progression or death (due to any cause). For patients who are alive with no hepatic progression, it will be defines as the time from the date of inclusion and the date of the last tumor assessment.", 
            "measure": "Rate of hepatic progression free survival at 24 months", 
            "safety_issue": "No", 
            "time_frame": "24 months after the last included patient"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival rate will be defined as the time from the date of inclusion to the date of disease progression (hepatic or not) evaluated by RECIST V1.1 criteria or death (due to any cause) or the date of the last morphological evaluation for patients who are alive with no disease progression.", 
                "measure": "Progression free survival rate (hepatic or not) at 24 months", 
                "safety_issue": "No", 
                "time_frame": "24 months after the last included patient"
            }, 
            {
                "description": "Overall survival rate shall be defined as the time from the date of inclusion to the date of death, regardless of the cause of death, or the date of last contact for patients who are alive.", 
                "measure": "Overall survival rate", 
                "safety_issue": "No", 
                "time_frame": "24 months after the last included patient"
            }, 
            {
                "description": "the toxicities recorded at each monthly visit, described using -CTCAE version 4.0; grade 3 and 4 toxicities will be reviewed;", 
                "measure": "Toxicities treatment", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after the last included patient"
            }, 
            {
                "description": "the number and description of SAEs;", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after the last included patient"
            }, 
            {
                "description": "the duration of treatment, the doses received, dose reductions, and deferred administrations;", 
                "measure": "Tolerability of the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after the last included patient"
            }
        ], 
        "source": "Federation Francophone de Cancerologie Digestive", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federation Francophone de Cancerologie Digestive", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}